Thus, further studies are needed to explore the role of IL-17A in atherosclerosis to evaluate a potential therapeutic strategy targeting IL-17, even though IL-17A is involved in host defense against bacterial infections at the mucosa and involved in autoimmunity diseases. This evidence concerns the gene IL17A and autoimmune disease.